Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.6.1.3 (ATPase)
65,361 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Caldesmon interacts with the NH2-terminal region of actin. It is now shown in airfuge centrifugation experiments that modification of the penultimate cysteine residue of actin significantly weakens its binding to caldesmon both in the presence and absence of tropomyosin. Furthermore, as revealed by fluorescence measurements, caldesmon increases the exposure of the COOH-terminal region of actin to the solvent. This effect of caldesmon, like its inhibitory effect on actomyosin ATPase activity, is enhanced in the presence of tropomyosin. Proteolytic removal of the last three COOH-terminal residues of actin, containing the modified cysteine residue, restores the normal binding between caldesmon and actin. These results establish a correlation between the binding of caldesmon to actin and the conformation of the COOH-terminal region of actin and suggest an indirect rather than direct interaction between caldesmon and this part of actin.
...
PMID:The interaction of caldesmon with the COOH terminus of actin. 193 62

cDNA clones encoding two isoforms of chicken gizzard calponin, a recently identified actin- and tropomyosin-binding protein, have been isolated and sequenced. The deduced polypeptides, 292 (Mr 32,333) and 252 (Mr 28,127) amino acids, contain sequences homologous to: a smooth muscle protein SM22 alpha, the Drosophila melanogaster mp20 gene product, troponin T, troponin I, and caldesmon. Calponin mRNAs of approximately 1.3 kilobases, encoding both isoforms, were expressed in all chicken smooth muscle tissues examined. These data, coupled with the inhibition of actomyosin ATPase by calponin (Winder, S. J., and Walsh, M. P. (1990) J. Biol. Chem. 265, 10148-10155; Abe, M., Takahashi, K., and Hiwada, K. (1990) J. Biochem. (Tokyo) 108, 835-838), suggest that calponin may function as a troponin homolog involved in the regulation of thin filament activity.
...
PMID:Molecular cloning and sequence analysis of smooth muscle calponin. 207 3

The amino-terminal region of muscle tropomyosin is highly conserved among muscle and 284-residue non-muscle tropomyosins. Analysis of fusion and nonfusion striated alpha-tropomyosins and a mutant in which residues 1-9 have been deleted has shown that the amino terminus is crucial for function. The presence of 80 amino acids of a nonstructural influenza virus protein (NS1) on the amino terminus of tropomyosin allows magnesium-independent binding of tropomyosin to actin. The fusion tropomyosin inhibits the actomyosin S1 ATPase at all myosin S1 concentrations tested, indicating that the presence of the fusion peptide prevents myosin S1 from switching the actin filament from the inhibited to the potentiated state. Nonfusion tropomyosin, an unacetylated form, has no effect on the actomyosin S1 ATPase, though it regulates normally with troponin. Deletion of residues 1-9, which are believed to overlap with the carboxyl-terminal end of tropomyosin in the thin filament, results in loss of tropomyosin function. The mutant is unable to bind to actin, in the presence and absence of troponin, and it has no regulatory function. The removal of the first 9 residues of tropomyosin is much more deleterious than removal of the last 11 by carboxypeptidase digestion. We suggest that the structure of the amino-terminal region and acetylation of the initial methionine are crucial for tropomyosin function.
...
PMID:The amino terminus of muscle tropomyosin is a major determinant for function. 213 42

The mechanism for the potentiation of the actin-activated ATPase of smooth muscle myosin by tropomyosin is investigated using smooth muscle actin, tropomyosin, and heavy meromyosin. In the presence of tropomyosin, an increase in Vmax occurs with no effect on KATPase and Kbinding at 20 mM ionic strength. Utilizing N-ethylmaleimide-treated subfragment-1, which forms rigor complexes with actin in the presence of ATP but does not have ATPase activity, experiments were carried out to determine if the tropomyosin-actin complex exists in both the turned-off and turned-on forms as in the skeletal muscle system. At both 60 and 100 mM ionic strengths, the presence of rigor complexes on the smooth muscle actin filament containing bound tropomyosin causes a 2-3-fold increase in Vmax and about a 3-fold increase in KATPase, resulting in about a 4-fold increase in ATPase activity at moderate actin concentration. The increase in KATPase is correlated with an increase in Kbinding. The finding that rigor complexes increase Vmax and the binding constant for heavy meromyosin to tropomyosin-actin at an ionic strength close to physiological conditions indicates that the tropomyosin-actin complex can be turned on by rigor complexes in a cooperative manner. However, in contrast to the situation in the skeletal muscle system, the increase in KATPase is associated with a corresponding increase in Kbinding. Furthermore, there is only a 3-fold increase in KATPase in the smooth muscle system rather than a 10-fold increase as in the skeletal muscle system.
...
PMID:Cooperativity of actin-activated ATPase of gizzard heavy meromyosin in the presence of gizzard tropomyosin. 213 24

We have shown in genetic myopathic hamsters that cardiac myofibrillar ATPase regulation by calcium is altered and that there are shifts in myosin isozyme distribution (V1----V3) suggesting abnormalities in multiple components of the contractile apparatus. To focus more on the regulatory proteins (troponin and tropomyosin), individual proteins of the skeletal and cardiac actomyosin system were reconstituted under controlled conditions. In this way, myosin plus actin and troponin-tropomyosin from the normal and myopathic animals could be studied enzymatically. The proteins were isolated from the skeletal or cardiac muscle of random-bred control and cardiomyopathic hamsters (BIO 53:58) at 7 months of age. Sodium dodecyl sulfate gel electrophoretic patterns indicated differences in the troponin I and troponin C regions of myopathic skeletal muscle, but cardiac samples from control and myopathic hamsters showed similarities in their mobilities. This suggests the possibility of different cardiac isozymes in the regulatory protein complex, as reported in our previous studies of cardiac myosin in cardiomyopathy. Calcium sensitivity was markedly decreased in the actomyosin reconstituted with troponin-tropomyosin from skeletal as well as cardiac muscle from myopathic animals. In summary, our data show that the regulatory proteins in skeletal and cardiac muscle of the myopathic hamsters have decreased inhibitory action on Mg2(+)-actomyosin ATPase activity. This loss of calcium regulation along with shifts in cardiac myosin heavy chain may be partially responsible for the impaired cardiac function in the hearts of myopathic hamsters.
...
PMID:Regulatory proteins in hamster cardiomyopathy. 213 21

Cardiac myofibrils from cardiomyopathic hamsters exhibit elevated Mg2+ ATPase activity and a parallel upward shift of the calcium ATPase dose response curve. To explore the mechanism, myofibrils from control and cardiomyopathic hamster hearts were incubated with isolated troponin-tropomyosin complex (Tn.Tm) from cardiomyopathic and control hamster or from dog hearts. Tn.Tm from control hamster or dog hearts restored normal Mg2+ ATPase activities to myofibrils from myopathic hearts. However, the maximum ATPase response to calcium stimulation was less in cardiomyopathic myofibrils compared to controls, even when control Tn.Tm was included. Electrophoretic patterns of Tn.Tm from myopathic and control hearts were similar. Electrophoresis of the hamster myofibrils mixed with dog cardiac Tn.Tm and then washed demonstrated binding of this complex to myopathic myofibrils. To further confirm that the incubation experiments resulted in binding, 125I troponin-tropomyosin was cross-hybridized with myofibrils, extensively washed, and then analyzed enzymatically and autoradiographically. Autoradiograms demonstrated similar percent binding of 125I Tn.Tm to all myofibrillar preparations and enzymatic effects like those found using cold Tn.Tm. These studies suggest that Tn.Tm from cardiomyopathic hearts inhibits Mg2+ myofibrillar ATPase activity to a lesser degree than Tn.Tm from control hearts. Decreased stimulation by calcium in myopathic preparations may be due to abnormalities in troponin-tropomyosin and/or to the decreased myosin ATPase activity observed previously.
...
PMID:Troponin-tropomyosin abnormalities in hamster cardiomyopathy. 214 67

A new method for the preparation of smooth muscle thin filaments which include calponin was established. We found that calponin readily separated from thin filaments in the presence of 10 mM ATP. By preventing thin filament extract from exposing to ATP, we obtained thin filaments which contained actin, tropomyosin, caldesmon and calponin in molar ratios of 7:0.9:0.6:0.7. We studied myosin Mg-ATPase activity by using the thin filaments in comparison with classical thin filaments prepared by the method of Marston and Smith, which contained the same amounts of caldesmon and tropomyosin as our thin filaments but lost almost all calponin. The presence of calponin reduced the Vmax value for thin filament-activated myosin Mg-ATPase activity by 33% without a significant change in Km value. These findings suggest that calponin inhibits myosin Mg-ATPase activity by modulation of a kinetic step as an integral component of smooth muscle thin filaments.
...
PMID:Do thin filaments of smooth muscle contain calponin? A new method for the preparation. 214 83

Analysis of the periodic distribution of amino acids in tropomyosin has revealed the presence of seven or 14 quasi-equivalent actin-binding sites. We tested the hypothesis of periodic actin-binding sites by making deletions of chicken striated alpha-tropomyosin cDNA using oligonucleotide-directed mutagenesis. The deletions corresponded to one-half (amino acid residues 47 to 67), two-thirds (residues 47 to 74) and one actin-binding site (residues 47 to 88), on the basis of there being seven sites. The mutant cDNAs were expressed as fusion and non-fusion proteins in Escherichia coli and analyzed for actin binding and regulatory function. Fusion tropomyosin binds to actin with an affinity similar to that of muscle tropomyosin. Of the mutant fusion tropomyosins, only that with a full site deleted retained actin affinity and the ability to inhibit the actomyosin S1 ATPase, though it was less effective than wild-type. We conclude that an integral number of half-turns of the tropomyosin coiled-coil, and the consequential sevenfold periodicity, as well as the correct orientation of the ends with respect to each other, are important for actin binding. On the other hand, non-fusion tropomyosin binds well to actin only in the presence of troponin, and the binding is calcium-sensitive. Assay of non-fusion mutant tropomyosins showed that mutants with deletion of one-half and one actin binding site both had high affinity for actin, equal to or slightly less than wild-type. The ability of these two mutants to regulate the actomyosin or acto-S1 ATPase with troponin in the absence of calcium was indistinguishable from that of the wild-type. The normal regulatory function of the mutant with a 1/14 deletion (removal of a quarter turn or half a site) indicates that a 14-fold periodicity is adequate for regulation, consistent with the presence of two sets of seven alpha and seven beta quasi-equivalent actin-binding sites. An alternative explanation is that the alpha-sites are of primary importance and that proper alignment of the alpha-sites in every second tropomyosin, as when half a site is deleted, is sufficient for normal regulatory function. Deletion of a non-integral period (2/3 of a site) severely compromised actin-binding and regulatory function, presumably due to the inability of the mutant to align properly on the actin filament.
...
PMID:Tropomyosin has discrete actin-binding sites with sevenfold and fourteenfold periodicities. 214 87

The cDNA coding for human skeletal muscle beta-tropomyosin was expressed in Escherichia coli to produce an unacetylated beta-tropomyosin. This cDNA was deleted from the sequence corresponding to the exon 9 and expressed in E. coli to produce an unacetylated beta-tropomyosin mutant lacking the C-terminal residues 254-284. The main structural and functional properties of the two isolated proteins, designated tropomyosin-1 and des-(254-284)-tropomyosin, respectively, were characterized in comparison with those of the genuine rabbit skeletal muscle alpha beta-tropomyosin. The folding and thermal stability of the three tropomyosins were indistinguishable. Tropomyosin-1, but not des-(254-284)-tropomyosin, was polymerized in the presence of troponin and did bind to actin in the presence of the troponin complex. Despite its weak binding to actin, des-(254-284)-tropomyosin displayed a regulatory function in the presence of troponin with a marked activation of the actomyosin subfragment-1 ATPase in the presence of Ca2+ and low concentrations of subfragment-1. The data were interpreted in the light of the allosteric models of regulation and suggest the involvement of the sequence coded by exon 9 in the stabilization by tropomyosin of the off state of the thin filament.
...
PMID:Construction, expression and unexpected regulatory properties of a tropomyosin mutant with a 31-residue deletion at the C-terminus (exon 9). 214 19

An unsplitable analogue of ATP (adenylyl imidodiphosphate; AMPPNP) was incorporated into F-actin [Cooke, R. (1975) Biochemistry 14, 3250-3256]. The resulting polymers (F-actin-AMPPNP) activated the ATPase activity of myosin subfragment-1 (S1) as efficiently as normal F-actin; neither the maximum velocity at infinite actin concentration (Vmax) nor the affinity of actin to S1 in the presence of ATP (1/KATPase) changed, which indicates that the terminal phosphate of the bound nucleotide at the cleft region between the two domains of the actin molecule [Kabsch, W., Mannherz, H.G., & Suck, D. (1985) EMBO J. 4, 2113-2118] is not directly involved in a myosin binding site. However, the interaction of F-actin with troponin-tropomyosin was strongly modulated by the replacement of ADP with AMPPNP. The troponin-tropomyosin complex strongly enhanced the activation of S1-ATPase activity by F-actin-AMPPNP in the presence of Ca2+, although it has no effect on the activation by normal F-actin-ADP. KATPase was enhanced about threefold by troponin-tropomyosin in the presence of Ca2+, while Vmax was not markedly changed. F-actin-AMPPNP is highly potentiated by troponin-tropomyosin even with low S1 to actin ratios and at high ATP conditions. In the absence of Ca2+, the activation by F-actin-AMPPNP was inhibited normally by troponin-tropomyosin. The results suggest that the terminal beta-phosphate of the bound nucleotide in F-actin is located in a region which is important for regulation of the interaction with myosin.
...
PMID:Interaction of F-actin-AMPPNP with myosin subfragment-1 and troponin-tropomyosin: influence of an extra phosphate at the nucleotide binding site in F-actin on its function. 214 37


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---